Ovid Therapeutics (OVID) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

OVID · Stock Price

USD 2.73+2.44 (+841.38%)

Market Cap: $471.5M

Historical price data

Overview

Ovid Therapeutics is a New York-based biotech dedicated to conquering rare neurological diseases through courageous science. Founded in 2014, the company has evolved its pipeline to focus on next-generation mechanisms for treatment-resistant seizures and neurodevelopmental disorders, including its lead GABA-AT inhibitor OV329 and KCC2 activator platform. While its former lead asset, soticlestat, is partnered with Takeda, Ovid is now advancing a wholly-owned, precision-focused pipeline for high-need patient communities with significant unmet medical need.

Rare Neurological DiseasesEpilepsyNeurodevelopmental Disorders

Technology Platform

Ovid employs a precision neurology strategy focused on novel mechanisms to modulate neuronal excitability, with specific platforms for direct KCC2 activation, ROCK2 inhibition, and gene therapy for CNS disorders.

Opportunities

The significant unmet need in treatment-resistant epilepsies and rare neurodevelopmental disorders offers a substantial market for novel, effective therapies.

Ovid's focus on novel mechanisms like KCC2 activation and gene therapy positions it at the forefront of precision neurology, with potential for regulatory incentives like Orphan Drug Designation.

Risk Factors

Ovid faces high clinical trial risk with its lead asset, imminent need for dilutive capital raises, and intense competition from larger, better-funded entities in the neurology space.

Its platforms are early-stage and scientifically unproven in humans.

Competitive Landscape

Ovid competes in the crowded rare neurology space against companies like Marinus, Neurocrine, and Sage Therapeutics, as well as gene therapy firms like Ultragenyx. Its differentiation lies in its novel mechanisms (GABA-AT, KCC2) and experienced CNS-focused team, but it faces constant pressure from competitors with greater resources.

More companies in Rare & Orphan Diseases →More companies in United States →